Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 -1.25%56 PS Ratio is 18.55 as of Jul. 17, 2026, which is 62% below its 10-year median of 49.29. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.77 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 954 Drug Manufacturers companies, Perseus Proteomics ranks worse than 93.19% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Perseus Proteomics's share price is 円158.00.
Perseus Proteomics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円8.52. Hence, Perseus Proteomics's PS Ratio for today is 18.55.
Good Sign:
Perseus Proteomics Inc stock PS Ratio (=17.38) is close to 10-year low of 16.06.
The historical rank and industry rank for Perseus Proteomics's PS Ratio or its related term are showing as below:
TSE:4882'
s PS Ratio Range Over the Past 10 Years
Min: 16.06 Med: 49.29 Max: 121.4
Current: 18.55
During the past 9 years, Perseus Proteomics's highest PS Ratio was 121.40. The lowest was 16.06. And the median was 49.29.
TSE:4882's PS Ratio is ranked worse than 93.19% of 954
companies
in the Drug Manufacturers industry
Industry Median: 2.325
vs TSE:4882: 18.55
During the past 12 months, the average Revenue per Share Growth Rate of Perseus Proteomics was 7.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 1.40% per year.
During the past 9 years, Perseus Proteomics's highest 3-Year average Revenue per Share Growth Rate was 8.90% per year. The lowest was -40.00% per year. And the median was -4.75% per year.
Back to Basics: PS Ratio
Perseus Proteomics (TSE:4882) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Perseus Proteomics PS Ratio Related Terms
Perseus Proteomics PS Ratio Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Perseus Proteomics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Perseus Proteomics's Share Price of today is 円158.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Perseus Proteomics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円8.52.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Perseus Proteomics (TSE:4882) has a PS Ratio of 18.55 as of Jul. 17, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Perseus Proteomics and its competitors. This is 62% below median its historical median of 49.29. Over the past decade, Perseus Proteomics' PS Ratio has ranged from 16.06 to 121.40. According to the industry distribution chart, Perseus Proteomics ranks #889 out of 954 companies in the Drug Manufacturers industry, placing it in the top 93.2%.
Is Perseus Proteomics' PS Ratio too high?
Perseus Proteomics' current PS Ratio of 18.55 is 62% below median its 10-year median of 49.29. Over the past 10 years, this metric has ranged from a low of 16.06 to a high of 121.40. The Drug Manufacturers industry median PS Ratio is 2.33. Perseus Proteomics' value of 18.55 is 697.8% above this industry median. Based on the distribution chart, Perseus Proteomics ranks #889 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' PS Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #889 out of 954 companies for PS Ratio. This places Perseus Proteomics in the lower half of its industry. The industry median PS Ratio is 2.33. Perseus Proteomics' value of 18.55 is 697.8% above this benchmark. Historically, Perseus Proteomics' own PS Ratio has ranged from 16.06 to 121.40 over the past decade. While the company's 10-year median is 49.29 vs. the industry median of 2.33, Perseus Proteomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.33, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perseus Proteomics's current PS Ratio of 18.55 is 697.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current PS Ratio is 18.55, which is 62% below median its own 10-year median of 49.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.77, compared to a current price of 円158.00 — trading 64.1% below its estimated fair value. The current PS Ratio is 18.55, which is 62% below median its 10-year median of 49.29 and 697.8% above the Drug Manufacturers industry median of 2.33. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current PS Ratio is 18.55 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円158.00 is trading 64.1% below its estimated GF Value™ of 円439.77.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
PS Ratio: 18.55 (62% below median its 10-year median of 49.29)
GF Value™: 円439.77 vs. price of 円158.00 (64.1% below fair value)
Industry Position: 697.8% above the Drug Manufacturers median (#889 of 954)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
